Do new psoriasis biologics have better safety profiles than adalimumab?
Authors of a registry study published in the JEADV analyzed the safety of biologic drugs and new oral molecules used to treat moderate-to-severe psoriasis compared to adalimumab. The safety profiles of biologic agents (etanercept, infliximab, adalimumab, certolizumab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab and tildrakizumab), apremilast, and dimethyl fumarate were studied.
Adalimumab had an incidence rate for all adverse events of 614 per 1000 patient-years. The risk of all adverse events was significantly lower for guselkumab, risankizumab, tildrakizumab, ixekizumab, and ustekinumab compared to adalimumab. The risk for all adverse events was significantly higher for dimethyl fumarate, infliximab, and apremilast, the last of which was not statistically significant. The risk of malignant neoplasms was significantly reduced in the group treated with ixekizumab.
Time to reassess messing around with steroids and psoriasis. Read more.
DermWorld Insights and Inquiries: Erectile dysfunction in dermatology — A silent epidemic
A privilege of being a physician is having intimate conversations with patients that would never occur in any other circumstances. Although I do not focus on sexual health during my patient encounters, it is discussed when obvious and appropriate, such as dyspareunia in women with lichen sclerosus. But what about men who may be afflicted with erectile dysfunction (ED) when the cause is not so apparent? ED is associated with chronic inflammatory disorders, including psoriasis, seborrheic dermatitis, hidradenitis suppurativa, atopic dermatitis, and others. We can do our patients a tremendous service, even if all we do is determine if they are experiencing ED and refer them to those with expertise in sexual health. Keep reading!
AAD seeks member comments for pediatric AD guidelines
The Academy is seeking member comments on the draft atopic dermatitis clinical guidelines for pediatrics. The guideline workgroup, which includes experts in pediatric AD management and a patient representative, will review your comments and edit the guidelines based on your feedback if applicable.Read the draft guidelines and submit your comments by Oct. 28.
FDA approves cemiplimab for adjuvant treatment of cutaneous squamous cell carcinoma
The FDA approved cemiplimab-rwlc for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation. In the randomized, double-blind, multicenter, placebo-controlled trial, patients were required to complete adjuvant radiation therapy within two to 10 weeks of randomization. The primary efficacy outcome measure was disease-free survival (DFS) defined as the time from randomization to the first documented disease recurrence or death due to any cause. Median DFS was not reached in the cemiplimab arm and was 49.4 months in the placebo arm.
The recommended dose is 350 mg intravenously every three weeks for 12 weeks, followed by 700 mg every six weeks, or 350 mg every three weeks until disease recurrence, unacceptable toxicity, or up to 48 weeks.
Melanoma rates after in vitro fertilization
Authors of a Brief Report in JAAD examined the association between IVF and malignant melanoma (MM). Overall, 113,292 MM female patients and 113, 292 matched controls were included. Subjects with MM versus without more often had prior IVF and gonadotropic therapy. Similar MM rates were observed in patients with infertility with versus without IVF, ovulation stimulant, gonadotropin, or both ovulation stimulant and gonadotropin exposure. The researchers found no association between IVF treatment, gonadotropin, or ovulation stimulant exposure and MM.
The American Academy of Dermatology is a non-profit professional organization and does not endorse companies or products. Advertising helps support our mission.
